Key Takeaway: The article discusses the administration of a dual-coated sodium phenylbutyrate suspension, known as Olpruva, via a gastrostomy tube. It provides an overview of the product and its application but lacks detailed information on clinical outcomes or specific events related to its use. The content appears to be more informational than newsworthy.
Price reaction · baseline $12.07 (2025-07-18 close) · clean, no other ZVRA news in the window
day 0 close · peak
-2.8%
Market Sentiment Analysis
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+71%
120-day peak, hindsight
Typical move
10.7%
average across 6 past catalysts
Lead asset
KP415
Phase 3 · ADHD
Full Press Release Details
• Overview
• Events & Presentations
• Stock Information
• - Stock Quote & Chart
• - Historic Stock Lookup
• - Analyst Coverage
• Press Releases
• Corporate Governance
• - Committee Composition
• - IRS – Required Disclosures
• Financials
• - SEC Filings
• - Quarterly Results
• - Annual Reports & Proxy
• State Compliance
• Email Alerts
• FAQs
ADMINISTRATION OF A DUAL-COATED SODIUM PHENYLBUTYRATE (OLPRUVA) SUSPENSION VIA GASTROSTOMY TUBE